Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy
- Conditions
- NeoplasmFunctional Gastrointestinal Disorder
- Interventions
- Dietary Supplement: placeboDietary Supplement: AC-Can
- Registration Number
- NCT01287286
- Lead Sponsor
- Chang Gung Memorial Hospital
- Brief Summary
The purpose of this study is to investigate if food supplements,Antrodia cinnamomea, could minimize the gastrointestinal symptom of cancer patients with chemotherapy.
- Detailed Description
In our unpublished report shows that patients who took Antrodia Cinnamomea compound of 15 milliliters liquid twice in a day, might help white blood cells, red blood cells and hemoglobin increase after 2 months; liver glutamic pyruvic transaminase(GPT) index mitigation, P \<0.05 difference statistically; In addition, liver glutamate oxaloacetate transaminase(GOT) and biochemical index of renal function had no abnormal data statistically. However, cancer patients with gastrointestinal disorders after chemotherapy is known to be a common side effect, we seek to investigate if Antrodia Cinnamomea improves the function of gastrointestinal system.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 64
- Histologically or cytologically confirmed Cancer.
- Age ≦ 80 years old and ≧ 18 years old.
- Eastern Cooperative Oncology Group(ECOG) performance status of 0-2.
- Adequate organ function, including followings Hepatic: Total bilirubin level ≦1.5 x UNL, GOT and GPT ≦ 2.5 x UNL if no liver metastasis; GOT and GPT ≦ 5 x UNL if liver metastasis. Renal: Creatinine level< 1.5 milligram per deciliter or Estimated creatinine clearance(CCr) ≧ 60 milliliter per minute (CCr is estimated by Cockcroft-Gault formula, as appendix II)
- Estimated life expectancy of at least 12 weeks.
- Written(signed) Informed Consent
- Ever treated and poor tolerance with platinum-based or anthracycline- based regimen, likely nausea and vomiting.
- Prior participation in any investigational drug study within 28 days
- Active uncontrolled infections or human immunodeficiency virus(HIV) infection
- Significant concurrent medical diseases, such as congestive heart failure, unstable angina, acute or recent myocardial infarction( 6 months before randomization), chronic obstructive pulmonary disease with frequent exacerbation, chronic renal diseases (estimated CCr 60 milliliter per minute), uncontrolled diabetes, uncontrolled hypertension, recent cerebrovascular disease episode( 6 months before randomization )
- With clinically significant Gastrointestinal disorder (e.g. bleeding, inflammation, obstruction or diarrhea)
- Psychiatric disorders that would compromise the patient's compliance or decision.
- Pregnancy or breast feeding.
- Known hypersensitivity to the component of investigational drugs.
- Known or suspected Gilbert's syndrome
- Poor compliance
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description control placebo Placebo and concomitant chemotherapy AC-Can AC-Can Antrodia cinnamomea and concomitant chemotherapy
- Primary Outcome Measures
Name Time Method Gastrointestinal symptoms in case group reduces 10% than control group during chemotherapy. 1 month Post-chemotherapy nausea, vomiting and epigastragia, etc. including gastrointestinal symptom/sign without mention above.
- Secondary Outcome Measures
Name Time Method Life quality estimates of 10% improvement than control group. 3 months Life science related questionnairs visit 4 times just before treatment, after intervention 7 days, 30 days and 90 days.
Trial Locations
- Locations (1)
Division of Haematology and Oncology, Department of Internal Medicine and Traditional Chinese Medicine, Chang Gung Memorial Hospital - Kaohsiung Medical Center
🇨🇳Niaosong, Kaohsiung, Taiwan